ALNY:NGS-Alnylam Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 147.4

Change

-0.49 (-0.33)%

Market Cap

USD 3.92B

Volume

0.54M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B
BMRN Biomarin Pharmaceutical Inc

-3.23 (-4.62%)

USD 13.32B

ETFs Containing ALNY

GNOM Global X Genomics & Biote.. 7.72 % 0.00 %

-0.02 (0.42%)

USD 0.08B
GNOG:LSE Global X Genomics & Biote.. 7.71 % 0.00 %

+0.02 (+0.42%)

USD 5.77M
GN0M:XETRA Global X Genomics & Biote.. 6.79 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 6.79 % 0.00 %

N/A

USD 5.93M
MSGR 6.64 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

-0.06 (0.42%)

N/A
CURG:LSE VanEck Genomics and Healt.. 5.47 % 0.00 %

+0.06 (+0.42%)

USD 5.12M
BMED BlackRock Future Health E.. 4.41 % 0.00 %

-0.02 (0.42%)

USD 4.17M
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

-0.15 (0.42%)

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 3.80 % 0.00 %

-0.02 (0.42%)

USD 0.52B
2B70:F iShares NASDAQ US Biotech.. 3.78 % 0.00 %

N/A

USD 0.52B
IBBQ Invesco Nasdaq Biotechnol.. 3.73 % 0.00 %

-0.11 (0.42%)

USD 0.04B
BBH VanEck Biotech ETF 3.71 % 0.35 %

-0.05 (0.42%)

USD 0.45B
IBB iShares Biotechnology ETF 3.62 % 0.47 %

-0.01 (0.42%)

USD 7.39B
QQQN VictoryShares Nasdaq Next.. 3.60 % 0.00 %

N/A

USD 0.02B
FBT:LSE First Trust Global Funds .. 3.53 % 0.00 %

+19.60 (+0.42%)

USD 8.17M
FBTU:LSE First Trust Global Funds .. 3.53 % 0.00 %

+0.27 (+0.42%)

USD 8.17M
FCUS Pinnacle Focused Opportun.. 3.35 % 0.00 %

-0.09 (0.42%)

USD 0.04B
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

N/A

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 3.00 % 0.00 %

-0.12 (0.42%)

USD 0.02B
BBP Virtus LifeSci Biotech Pr.. 2.74 % 0.79 %

-0.56 (0.42%)

USD 0.02B
CURE:AU ETFS S&P Biotech ETF 2.62 % 0.00 %

+0.15 (+0.42%)

USD 0.04B
BIB ProShares Ultra Nasdaq Bi.. 2.58 % 0.95 %

-0.61 (0.42%)

USD 0.09B
EQJS:LSE Invesco NASDAQ Next Gener.. 2.48 % 0.00 %

-8.50 (0.42%)

USD 0.05B
QQQJ Invesco NASDAQ Next Gen 1.. 2.47 % 0.00 %

-0.15 (0.42%)

USD 0.68B
FXH First Trust Health Care A.. 2.45 % 0.63 %

+0.33 (+0.42%)

USD 1.18B
FHH:CA First Trust AlphaDEX US H.. 2.35 % 0.77 %

+0.30 (+0.42%)

CAD 0.01B
FHH-F:CA First Trust AlphaDEX U.S... 2.35 % 0.00 %

N/A

CAD 0.01B
ZUH:CA BMO Equal Weight US Healt.. 2.30 % 0.39 %

+0.10 (+0.42%)

CAD 0.26B
ZHU:CA BMO Equal Weight US Healt.. 2.30 % 0.00 %

+0.05 (+0.42%)

CAD 0.01B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.29 % 0.00 %

-0.31 (0.42%)

USD 0.05B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

-0.01 (0.42%)

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

N/A

N/A
TMFX Motley Fool Next Index ET.. 2.06 % 0.00 %

-0.07 (0.42%)

USD 0.03B
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

-0.23 (0.42%)

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

-2.65 (0.42%)

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.87 % 0.00 %

-0.08 (0.42%)

N/A
ETHO Amplify ETF Trust 0.68 % 0.45 %

+0.01 (+0.42%)

USD 0.18B
IUSF:LSE iShares IV Public Limited.. 0.54 % 0.00 %

+1.75 (+0.42%)

USD 0.25B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.54 % 0.00 %

+0.03 (+0.42%)

USD 0.25B
QDVC:XETRA iShares Edge MSCI USA Siz.. 0.52 % 0.00 %

-0.04 (0.42%)

USD 0.19B
IUSZ:SW iShares Edge MSCI USA Siz.. 0.52 % 0.00 %

N/A

N/A
IWFS:LSE iShares MSCI World Size F.. 0.23 % 0.00 %

N/A

USD 0.28B
IWSZ:LSE iShares IV Public Limited.. 0.23 % 0.00 %

-0.01 (0.42%)

USD 0.28B
IS3T:XETRA iShares MSCI World Size F.. 0.21 % 0.00 %

-0.19 (0.42%)

USD 0.24B
IWSZ:SW iShares Edge MSCI World S.. 0.21 % 0.00 %

N/A

USD 0.28B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

-0.42 (0.42%)

N/A
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-0.42 (0.42%)

USD 0.91B
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.42%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.42%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-2.85 (0.42%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.42%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-0.14 (0.42%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

-0.08 (0.42%)

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

+0.09 (+0.42%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.99% 32% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.99% 32% F 23% F
Trailing 12 Months  
Capital Gain -23.72% 52% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.72% 52% F 31% F
Trailing 5 Years  
Capital Gain 118.24% 84% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 118.24% 84% B 84% B
Average Annual (5 Year Horizon)  
Capital Gain 20.83% 74% C 80% B-
Dividend Return 20.83% 74% C 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.23% 76% C+ 54% F
Risk Adjusted Return 60.85% 96% N/A 86% B+
Market Capitalization 3.92B 99% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 142.92 1% 1%
Price / Cash Flow Ratio 182.03 1% 1%
Price/Free Cash Flow Ratio -81.96 99% 97%
Management Effectiveness  
Return on Equity -1,500.66% 4% 2%
Return on Invested Capital -34.83% 71% 28%
Return on Assets -3.05% 94% 44%
Debt to Equity Ratio -462.63% 97% 98%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.